A small, ob­scure biotech just won big with their IPO. In this mar­ket. Are you kid­ding me?

6 years ago
Financing
Bioregnum

In­vest­ing in the time of coro­n­avirus: the good, the bad and the hope­ful, as biotech VC firms close funds worth $3B

6 years ago
Financing
In Focus

Covid-19 roundup: Mod­er­na CEO Stéphane Ban­cel be­comes a bil­lion­aire; No­var­tis, In­cyte pitch Jakafi PhI­II to tack­le ...

6 years ago
R&D
Coronavirus

J&J gives pi­o­neer­ing stem cell biotech its first Big Phar­ma deal, part­ner­ing on iP­SC CAR-T and CAR-NK

6 years ago
Deals

Drug dis­cov­ery in the age of coro­n­avirus

6 years ago
Biotech Voices
Coronavirus

Mer­ck scores new ad­vance on tu­mor-ag­nos­tic front as Keytru­da beat chemo-based reg­i­mens in a type of col­orec­tal can­cer

6 years ago
R&D
Pharma

Sue Desmond-Hell­mann joins Pfiz­er board; Kite Phar­ma taps al­ly in push to ex­pand CAR-T

6 years ago
News Briefing

FDA OKs a tri­al for a new Covid-19 ther­a­py af­ter an un­usu­al pub­lic­i­ty cam­paign touts its po­ten­tial — with help from ...

6 years ago
Bioregnum
R&D

Dy­nacure se­cures $55M as their Io­n­is-de­vel­oped drug moves in­to clin­ic

6 years ago
Financing
Cell/Gene Tx

Covid-19 roundup: Am­gen joins the race to de­vel­op a drug; Doc­tors, nurs­es em­ployed by Mer­ck, Lil­ly, Pfiz­er can pitch ...

6 years ago
Coronavirus

No­var­tis can­cels $1B sale of gener­ics af­ter an­titrust con­cerns forced de­lays

6 years ago
Deals

Step­ping out along­side ARCH's record raise, Flag­ship adds a $1.1B mon­ster fund of its own

6 years ago
Financing

ARCH chief Bob Nelsen has $1.5B to prove 2 sim­ple points: ‘We’re in the most in­no­v­a­tive time ever’ and ...

6 years ago
Financing

FDA seeks with­draw­al of heart­burn drugs due to new car­cino­gen con­cerns

6 years ago
FDA+

The race to de­vel­op Covid-19 drugs and vac­cines is on — here’s what’s hap­pen­ing in the UK

6 years ago
Coronavirus

‘There was a grow­ing weari­ness’: Rush­ing against a pan­dem­ic clock, As­pen Neu­ro­science se­cures $70M Se­ries A

6 years ago
Financing

Flex­ion se­cures Chi­na deal for os­teoarthri­tis drug; Strug­gling to find a buy­er, Ako­rn throws in the tow­el

6 years ago
News Briefing

FDA puts pe­di­atric aGVHD drug on pri­or­i­ty re­view lane — will they go vir­tu­al with the ad­comm?

6 years ago
Cell/Gene Tx
FDA+

Covid-19 roundup: Trump push­es his new fa­vorite, untest­ed drug; CRISPR out­lines crip­pling im­pact of Covid-19

6 years ago
Coronavirus

ITeos nabs $125M as they prep Keytru­da com­bi­na­tion tri­al — if Covid-19 will let them

6 years ago
Financing
R&D

Dai­ichi Sankyo sinks $200M in­to new gene ther­a­py tech from Ul­tragenyx

6 years ago
Deals
Cell/Gene Tx

Have a new drug that promis­es to fight Covid-19? The FDA promis­es fast ac­tion but some de­vel­op­ers aren't hap­py

6 years ago
FDA+
Coronavirus

Mo­tion de­nied: Gilead still on the hook for $1.5B in dam­ages over CAR-T patent dis­pute with Bris­tol My­ers Squibb

6 years ago
People
Cell/Gene Tx

A quiver of ar­rows for im­mune dis­or­ders: Pan­dion scores $80M in fresh fund­ing

6 years ago
Financing
Startups
First page Previous page 839840841842843844845 Next page Last page
A service from the Financial Times